Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
December 14 2017 - 4:01PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a
clinical-stage biopharmaceutical company dedicated to discovering,
developing and commercializing novel therapeutics to treat grievous
blood-based disorders with significant unmet need, today announced
an agreement to sell $100.0 million in shares of its common stock
in a registered underwritten public offering. In addition, GBT has
granted the underwriter a 30-day option to purchase up to $15.0
million in shares of its common stock.
Cantor Fitzgerald & Co. is acting as the sole book-running
manager for the offering.
GBT intends to use the net proceeds from the offering to fund
its clinical development of voxelotor for the treatment of sickle
cell disease, including its ongoing Phase 3 HOPE Study and its
ongoing Phase 2a HOPE-KIDS1 Study, as well as future clinical
trials, its other research and development activities, and for
working capital and general corporate purposes.
An automatic shelf registration statement relating to the shares
of common stock offered in the public offering described above was
filed with the Securities and Exchange Commission (SEC) on August
23, 2017 and automatically became effective upon filing. The
securities may be offered only by means of a written prospectus,
including a prospectus supplement, forming a part of the effective
registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and
the accompanying prospectus may also be obtained by contacting
Cantor Fitzgerald & Co., Attention: Capital Markets, 499
Park Ave., 6th Floor, New York, New York 10022, or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Global Blood TherapeuticsGlobal Blood
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
dedicated to discovering, developing and commercializing novel
therapeutics to treat grievous blood-based disorders with
significant unmet need. GBT’s lead product candidate is voxelotor
(formerly known as GBT440), an oral, once-daily therapy that
modulates hemoglobin’s affinity for oxygen, which the Company
believes inhibits hemoglobin polymerization in sickle cell
disease.
Forward-Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements about GBT’s anticipated public offering, anticipated use
of proceeds and other statements containing the words “anticipate,”
“planned,” “believe,” “forecast,” “estimated,” “expected,” and
“intend,” among others. These forward-looking statements are based
on GBT’s current expectations and actual results could differ
materially. Statements we make in this press release may include
statements that are not historical facts and are considered
forward-looking within the meaning of Section 27A of the Securities
Act of 1933, as amended and Section 21E of the Securities Exchange
Act of 1934, as amended. We intend these forward-looking
statements, including statements regarding the therapeutic
potential and safety profile of voxelotor (previously called
GBT440), our ability to implement and complete our clinical
development plans for voxelotor, our ability to generate and report
data from our ongoing and potential future studies of voxelotor
(including our ongoing Phase 3 HOPE study and our ongoing Phase 2a
HOPE-KIDS1 study), regulatory review and actions relating to
voxelotor, and the timing of these events, to be covered by the
safe harbor provisions for forward-looking statements contained in
Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act and are making this statement for purposes of
complying with those safe harbor provisions. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. We can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved, and
furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by
a variety of risks and factors that are beyond our control
including, without limitation, the risks that our clinical and
preclinical development activities may be delayed or terminated for
a variety of reasons, that results of clinical trials may be
subject to differing interpretations, that regulatory authorities
may disagree with our clinical development plans or require
additional studies or data to support further clinical
investigation of our product candidates, that drug-related adverse
events may be observed in clinical development, and that data and
results may not meet regulatory requirements or otherwise be
sufficient for further development, regulatory review or approval,
along with those risks set forth in our Annual Report on Form 10-K
for the fiscal year ended December 31, 2016, and in our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2017, as
well as discussions of potential risks, uncertainties and other
important factors in our subsequent filings with the U.S.
Securities and Exchange Commission. Except as required by law, we
assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact Information: Myesha Lacy
(investors)GBT650-351-4730investor@globalbloodtx.com
Julie Normart (media)Pure
Communications415-946-1087media@globalbloodtx.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024